TABLE 50Compatibility of the model with the NICE reference case

Element of health technology assessmentPrinciplesMet requirements of NICE reference case
Defining the decision problemThe scope developed by NICEYes
ComparatorAlternative therapies routinely used in the NHSPartial. Not all relevant comparators are used for the adalimumab
Perspective on costsNHS and PSSNHS only
Perspective on outcomesAll health effects on individualsYes
Type of economic evaluationCost-effectiveness analysisYes
Time horizonSufficient to reflect any differences in costs or outcomes between the technologies comparedNot applicable, given limits of evidence based
Synthesis of evidence on outcomesBased on a systematic reviewPartial. Details unclear and not necessarily reproducible
Measure of health benefitsQALYsYes
Description of health states for calculation of QALYsHealth states described using a standardised and validated generic instrumentYes
Method of preference elicitation for health-state valuationChoice-based method, for example, time trade-off, standard gamble (not rating scale)Yes
Source of preference dataRepresentative sample of the publicNo. Patient values used
Discount rateAn annual rate of 3.5% on both costs and health effectsYes
Equity positionAn additional QALY has the same weight regardless of the other characteristics of the individuals receiving the health benefitYes
Modelling methodsStructural assumptions and data inputs clearly documented and justifiedNo
Probabilistic sensitivity analysis should be conductedYes

From: 4, Assessment of cost-effectiveness

Cover of A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease
A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease.
Health Technology Assessment, No. 15.6.
Dretzke J, Edlin R, Round J, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.